Experimental cancer combo enters early human testing
NCT ID NCT07508761
First seen Jun 26, 2026 · Last updated Jun 30, 2026 · Updated 3 times
Summary
This early-phase trial tests a new oral drug called IPG7236 combined with the immunotherapy toripalimab in adults with advanced solid tumors that have spread or cannot be removed. The study has two parts: first, finding the safest dose of IPG7236, then expanding to see if the combination shrinks tumors. About 52 people will take part. The main focus is safety, but researchers will also check for any anti-cancer activity.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
IPG7236 (an experimental oral drug) combined with toripalimab (an immunotherapy injection)
What this could lead to
If successful, this combination could shrink tumors or slow cancer growth in people with advanced solid tumors that have not responded to other treatments.
What could go wrong
This is a very early, small trial (Phase 1/2) with only 52 participants. The main goal is safety, not effectiveness. Side effects could be serious, and the drug may not work against the cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai Gaobo Tumor Hospital
RECRUITINGShanghai, PuDongXinQu, 200120, China
Contact Phone: •••-•••-•••• Email: •••••@•••••